Enhabit (EHAB) Competitors $10.26 -0.17 (-1.58%) Closing price 05/22/2025 03:59 PM EasternExtended Trading$10.26 -0.01 (-0.05%) As of 05/22/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EHAB vs. ADUS, PGNY, PACS, WGS, NHC, TDOC, GRAL, AHCO, AGL, and AVAHShould you be buying Enhabit stock or one of its competitors? The main competitors of Enhabit include Addus HomeCare (ADUS), Progyny (PGNY), PACS Group (PACS), GeneDx (WGS), National HealthCare (NHC), Teladoc Health (TDOC), Grail (GRAL), AdaptHealth (AHCO), agilon health (AGL), and Aveanna Healthcare (AVAH). These companies are all part of the "healthcare" industry. Enhabit vs. Addus HomeCare Progyny PACS Group GeneDx National HealthCare Teladoc Health Grail AdaptHealth agilon health Aveanna Healthcare Addus HomeCare (NASDAQ:ADUS) and Enhabit (NYSE:EHAB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends, analyst recommendations and community ranking. Does the MarketBeat Community favor ADUS or EHAB? Addus HomeCare received 327 more outperform votes than Enhabit when rated by MarketBeat users. Likewise, 69.02% of users gave Addus HomeCare an outperform vote while only 17.24% of users gave Enhabit an outperform vote. CompanyUnderperformOutperformAddus HomeCareOutperform Votes33269.02% Underperform Votes14930.98% EnhabitOutperform Votes517.24%Underperform Votes2482.76% Do analysts rate ADUS or EHAB? Addus HomeCare currently has a consensus price target of $142.57, suggesting a potential upside of 27.83%. Enhabit has a consensus price target of $8.50, suggesting a potential downside of 17.19%. Given Addus HomeCare's stronger consensus rating and higher probable upside, research analysts clearly believe Addus HomeCare is more favorable than Enhabit.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addus HomeCare 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Enhabit 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders believe in ADUS or EHAB? 95.3% of Addus HomeCare shares are owned by institutional investors. 4.6% of Addus HomeCare shares are owned by insiders. Comparatively, 1.9% of Enhabit shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer ADUS or EHAB? In the previous week, Addus HomeCare had 4 more articles in the media than Enhabit. MarketBeat recorded 13 mentions for Addus HomeCare and 9 mentions for Enhabit. Enhabit's average media sentiment score of 1.39 beat Addus HomeCare's score of 0.85 indicating that Enhabit is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addus HomeCare 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enhabit 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, ADUS or EHAB? Addus HomeCare has higher revenue and earnings than Enhabit. Enhabit is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAddus HomeCare$1.21B1.69$62.52M$4.4325.18Enhabit$1.03B0.50-$80.50M-$2.77-3.71 Which has more risk and volatility, ADUS or EHAB? Addus HomeCare has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Enhabit has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Is ADUS or EHAB more profitable? Addus HomeCare has a net margin of 6.50% compared to Enhabit's net margin of -11.24%. Addus HomeCare's return on equity of 9.62% beat Enhabit's return on equity.Company Net Margins Return on Equity Return on Assets Addus HomeCare6.50% 9.62% 7.37% Enhabit -11.24%1.67%0.80% SummaryAddus HomeCare beats Enhabit on 17 of the 19 factors compared between the two stocks. Get Enhabit News Delivered to You Automatically Sign up to receive the latest news and ratings for EHAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EHAB vs. The Competition Export to ExcelMetricEnhabitHome health care services IndustryMedical SectorNYSE ExchangeMarket Cap$519.79M$3.16B$5.33B$19.30BDividend YieldN/A0.34%5.21%3.83%P/E Ratio-4.4229.4826.7934.53Price / Sales0.501.13393.6934.84Price / Cash3.2517.2938.2517.51Price / Book0.743.596.774.69Net Income-$80.50M-$57.02M$3.23B$1.02B7 Day Performance-3.57%-3.66%0.42%-2.43%1 Month Performance36.50%15.03%9.06%6.27%1 Year Performance11.82%26.93%18.55%5.78% Enhabit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EHABEnhabit2.0674 of 5 stars$10.27-1.6%$8.50-17.2%+9.0%$519.79M$1.03B-4.4210,900Positive NewsADUSAddus HomeCare4.7852 of 5 stars$110.55-0.3%$142.57+29.0%+1.1%$2.04B$1.21B25.3033,200PGNYProgyny1.4925 of 5 stars$22.00+3.8%$23.45+6.6%-21.9%$1.88B$1.17B37.93310Positive NewsPACSPACS Group3.4057 of 5 stars$11.12+6.6%$34.00+205.8%-64.6%$1.69B$3.56B0.0032,433Gap UpWGSGeneDx3.9509 of 5 stars$59.00-0.2%$86.57+46.7%+236.8%$1.66B$330.14M-30.101,200Positive NewsNHCNational HealthCareN/A$102.14+1.6%N/A+2.0%$1.58B$1.37B12.8012,400Positive NewsTDOCTeladoc Health3.6632 of 5 stars$7.36+3.4%$9.71+32.0%-42.0%$1.29B$2.55B-1.275,100Gap UpGRALGrail0.8006 of 5 stars$35.99+2.2%$26.00-27.8%N/A$1.27B$125.60M0.001,360Positive NewsGap UpAHCOAdaptHealth2.5578 of 5 stars$9.11+6.3%$13.40+47.1%-8.0%$1.23B$3.25B-5.5210,900Positive NewsAGLagilon health2.1339 of 5 stars$2.97+2.6%$4.89+65.0%-63.1%$1.23B$5.99B-3.15650AVAHAveanna Healthcare0.5795 of 5 stars$5.78+7.0%$5.13-11.3%+89.7%$1.13B$2.02B-17.0033,000Insider TradeHigh Trading Volume Related Companies and Tools Related Companies ADUS Competitors PGNY Competitors PACS Competitors WGS Competitors NHC Competitors TDOC Competitors GRAL Competitors AHCO Competitors AGL Competitors AVAH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:EHAB) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enhabit, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enhabit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
